Circular Genomics has partnered with PharmatrophiX to profile circular RNA in the blood of patients receiving LM11A-31, an experimental small molecule for Alzheimer's disease, with the aim of identifying who responds to treatment and why. Circular RNAs are closed-loop transcripts that are unusually stable in circulation, making them candidate peripheral readouts of brain activity. The CircPath platform used for the analysis is research-use-only and is not available for clinical ordering.
Key Points
- Blood circular RNA profiled in an active Alzheimer's drug trial
- Goal is distinguishing treatment responders from non-responders
- CircPath platform remains research-use-only, not clinically available
Longevity Analysis
Neurodegeneration remains among the hardest conditions to monitor, because the organ in question cannot be sampled directly and functional decline appears long after the underlying process begins. Stable circulating transcripts offer a potential way to read what is happening in neural tissue from a blood draw, shifting interpretation of cognitive change from inference to measurement. The more immediate value lies in stratification: knowing which individuals respond to a given intervention prevents years spent on therapies that were never going to work for that biology.
Original published by Longevity.Technology, by Kyle Umipig.